[About a patient with nalidixic-acid-resistant Salmonella enterica serotype typhi infection. Therapeutic management].
Juan José
JJ
González-López
Nieves
N
Larrosa
Ana M
AM
Planes
Rosa M
RM
Bartolomé-Comas
D000293:Adolescent; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D001426:Bacterial Proteins / Q000235:genetics; D002169:Campylobacter Infections / Q000150:complications / Q000188:drug therapy; D016123:Campylobacter jejuni; D027081:DNA Gyrase / Q000235:genetics; D004352:Drug Resistance, Microbial / Q000235:genetics; D005759:Gastroenteritis / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male; D020125:Mutation, Missense; D009268:Nalidixic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D010154:Pakistan / Q000208:ethnology; D012485:Salmonella typhi / Q000187:drug effects* / Q000235:genetics; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D014435:Typhoid Fever / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology
D001426:Bacterial Proteins; D009268:Nalidixic Acid; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D027081:DNA Gyrase